NCT07004413
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT07004413 |
| Title | Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients (FIRE-11) |
| Acronym | FIRE-11 |
| Recruitment | Not yet recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | Yes |
| Sponsors | Charite University, Berlin, Germany |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | DEU |
CKB BOOST